Hugo Vanderstichele

22.4k citations

156 papers · 14.8k indexed · 6 hit papers · h-index 57

Psychiatry and Mental health top 0.05%
- Dementia and Cognitive Impairment Research 72
Physiology top 0.05%
- Alzheimer's disease research and treatments 106
Neurology top 0.1%
- Parkinson's Disease Mechanisms and Treatments 17
- Neurological Disease Mechanisms and Treatments 11
Biological Psychiatry top 1%
Neurology top 0.5%
- Parkinson's Disease Mechanisms and Treatments 17
- Neurological Disease Mechanisms and Treatments 11
Molecular Biology
- Amyloidosis: Diagnosis, Treatment, Outcomes 14
- S100 Proteins and Annexins 10
Computational Theory and Mathematics
- Computational Drug Discovery Methods 12
Statistics and Probability
- Statistical Methods in Clinical Trials 9

Co-authors: Kaj Blennow Eugeen Vanmechelen Pia Davidsson Niels Andreasen Lennart Minthon Wim Annaert Paul Säftig Bart De Strooper
Cited by: Psychiatry and Mental health Physiology Neurology
Journals: Alzheimer s & Dementia (26 papers)Journal of Alzheimer s Disease (15 papers)Alzheimer s Research & Therapy (12 papers)
Partner nations: Belgium Sweden United States

In The Last Decade

Hugo Vanderstichele

155 papers receiving 14.5k citations

Hit Papers

6 papers align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2021 Translational Psychiatry
2016 Annals of Clinical and Translational Neurology
2009 Annals of Neurology
1999 Archives of Neurology
1999 Neurology
1998 Nature

Peers

Countries citing papers authored by Hugo Vanderstichele

Since Specialization

Citations

This map shows the geographic impact of Hugo Vanderstichele's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hugo Vanderstichele with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hugo Vanderstichele more than expected).

Fields of papers citing papers by Hugo Vanderstichele

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hugo Vanderstichele. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hugo Vanderstichele. The network helps show where Hugo Vanderstichele may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Hugo Vanderstichele, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Hugo Vanderstichele Line = papers co-authored together Hugo Vanderstichele links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Biofluid biomarker changes following treatment with sabirnetug (ACU193) in INTERCEPT-AD, a phase 1 trial in early Alzheimer's disease The Journal of Prevention of Alzheimer s Disease ·Erika N. Cline,M. Punturo,Karen Sundell,Elizabeth A. Johnson,Michael E. Hyland,Hao Zhang,Hugo Vanderstichele,June Kaplow,Robert A. Dean,Erik Stoops,Eugeen Vanmechelen,Marleen J.A. Koel‐Simmelink,Charlotte E. Teunissen,Gopalan Sethuraman,Liu Yu,Eric Siemers,Jasna Jerecı̀ć	2025	2
2	Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer’s diseasebreakdown → Translational Psychiatry ·Pratishtha Chatterjee,Steve Pedrini,Erik Stoops,Kathryn Goozee,Victor L. Villemagne,Prita R. Asih,Inge M.W. Verberk,Preeti Dave,Kevin Taddei,Hamid R. Sohrabi,Henrik Zetterberg,Kaj Blennow,Charlotte E. Teunissen,Hugo Vanderstichele,Ralph N. Martins	2021	276
3	Core Alzheimer’s disease cerebrospinal fluid biomarker assays are not affected by aspiration or gravity drip extraction methods Alzheimer s Research & Therapy ·James D. Doecke,Cindy François,Christopher Fowler,Erik Stoops,Pierrick Bourgeat,Stephanie R. Rainey‐Smith,Qiao‐Xin Li,Colin L. Masters,Ralph N. Martins,Victor L. Villemagne,Steven Collins,Hugo Vanderstichele	2021	0
4	Highly specific and ultrasensitive plasma test detects Abeta(1–42) and Abeta(1–40) in Alzheimer’s disease Scientific Reports ·Elisabeth H. Thijssen,Inge M.W. Verberk,Jeroen Vanbrabant,隆太郎鈴木,Hans Heijst,Philip Scheltens,Wiesje M. van der Flier,Hugo Vanderstichele,Erik Stoops,Charlotte E. Teunissen	2021	52
5	Effect of the micro-environment on α-synuclein conversion and implication in seeded conversion assays Translational Neurodegeneration ·Niccolò Candelise,Matthias Schmitz,Katrin Thüne,Maria Cramm,Alberto Rábano,Saima Zafar,Erik Stoops,Hugo Vanderstichele,Anna Villar‐Piqué,Franc Llorens,Inga Zerr	2020	57
6	C-Reactive Protein, Plasma Amyloid-β Levels, and Their Interaction With Magnetic Resonance Imaging Markers Stroke ·Saima Hilal,M. Arfan Ikram,Marcel M. Verbeek,Oscar H. Franco,Erik Stoops,Hugo Vanderstichele,Wiro J. Niessen,Meike W. Vernooij	2018	48
7	Cerebrospinal Fluid Total and Phosphorylated α-Synuclein in Patients with Creutzfeldt–Jakob Disease and Synucleinopathy Molecular Neurobiology ·Matthias Schmitz,Anna Villar‐Piqué,Franc Llorens,Karin Gmitterová,Péter Hermann,Daniela Varges,Saima Zafar,Paul Lingor,Hugo Vanderstichele,Flurina Bertschinger,Erik Stoops,John Q. Trojanowski,Virginia M.‐Y. Lee,Inga Zerr	2018	23
8	No diurnal variation of classical and candidate biomarkers of Alzheimer’s disease in CSF Molecular Neurodegeneration ·Claudia Cicognola,Davide Chiasserini,Paolo Eusebi,Ulf Andréasson,Hugo Vanderstichele,Henrik Zetterberg,Lucilla Parnetti,Kaj Blennow	2016	15
9	Diagnostic Impact of Cerebrospinal Fluid Biomarker (Pre-)Analytical Variability in Alzheimer’s Disease Journal of Alzheimer s Disease ·Ellis Niemantsverdriet,Xinling Li,Hanne Struyfs,Jean‐Jacques Martin,Johan Goeman,Peter Paul De Deyn,Hugo Vanderstichele,Sebastiaan Engelborghs	2016	20
10	Comparison of Analytical Platforms for Cerebrospinal Fluid Measures of β-Amyloid 1-42, Total tau, and P-tau₁₈₁ for Identifying Alzheimer Disease Amyloid Plaque Pathology Archives of Neurology ·Anne M. Fagan,Leslie M. Shaw,Chengjie Xiong,Hugo Vanderstichele,Mark A. Mintun,John Q. Trojanowski,Els Coart,John C. Morris,David M. Holtzman	2011	137
11	Added diagnostic value of CSF biomarkers in differential dementia diagnosis Neurodegenerative Diseases ·Nathalie Le Bastard,J.J. Martin,Eugeen Vanmechelen,Hugo Vanderstichele,Peter Paul De Deyn,Sebastiaan Engelborghs	2009	3
12	Analytical performance and clinical utility of the INNOTEST® PHOSPHO-TAU(181P) assay for discrimination between Alzheimer's disease and dementia with Lewy bodies Clinical Chemistry and Laboratory Medicine (CCLM) ·Hugo Vanderstichele,K De Vreese,Kaj Blennow,Niels Andreasen,Christian Sindic,Adrian Ivanoiu,Harald Hampel,Katharina Bürger,Lucilla Parnetti,Alessia Lanari,Alessandro Padovani,Mónica Di Luca,Niloofar Babadi,Annika Olsson,Hans Pottel,Frank Hulstaert,Eugeen Vanmechelen	2006	131
13	The Effect of Simvastatin Treatment on the Amyloid Precursor Protein and Brain Cholesterol Metabolism in Patients with Alzheimer’s Disease Dementia and Geriatric Cognitive Disorders ·Kina Höglund,Karin Thelen,Publisher Karthikeyan M Ramasamy,Magnus Sjögren,Klaus von Bergmann,Anders Wallin,Eugeen Vanmechelen,Hugo Vanderstichele,Dieter Lütjohann,Kaj Blennow	2005	77
14	Cerebrospinal Fluid Beta-Amyloid 42 Is Reduced before the Onset of Sporadic Dementia: A Population-Based Study in 85-Year-Olds Dementia and Geriatric Cognitive Disorders ·Ingmar Skoog,Pia Davidsson,Ólafur Aevarsson,Hugo Vanderstichele,Eugeen Vanmechelen,K. Blennow	2003	151
15	Glycosylation of acetylcholinesterase and butyrylcholinesterase changes as a function of the duration of Alzheimer's disease Journal of Neuroscience Research ·Javier Sáez‐Valero,Lisa R. Fodero,Magnus Sjögren,Nancy C. Andreasen,Serena Amici,Virgilio Gallai,Hugo Vanderstichele,Eugeen Vanmechelen,Lucilla Parnetti,Kaj Blennow,David H. Small	2003	50
16	Prominent Cerebral Amyloid Angiopathy in Transgenic Mice Overexpressing the London Mutant of Human APP in Neurons American Journal Of Pathology ·Jo Van Dorpe,Min Zhang,Ilse Dewachter,Dieter Nuyens,Kurt Spittaels,Chris Van den Haute,Marc Mercken,Dieder Moechars,S. Kaushal,Cuno Kuipéri,Koen Bruynseels,Ina Tesseur,Ruth J. F. Loos,Hugo Vanderstichele,Frédéric Checler,Raf Sciot,F. Van Leuven	2000	189
17	CSF levels of tau, β-amyloid 1-42 and GAP-43 in frontotemporal dementia, other types of dementia and normal aging Journal of Neural Transmission ·Magnus Sjögren,Lennart Minthon,Pia Davidsson,Ann‐Kathrine Granérus,José María,Hugo Vanderstichele,Eugeen Vanmechelen,Anders Wallin,Kaj Blennow	2000	205
18	Disease- and treatment-related elevation of the neurodegenerative marker tau in children with hematological malignancies Leukemia ·E. Nieschlag,E Van Kerschaver,Penelope Brock,Hans Pottel,Frank Hulstaert,Eugeen Vanmechelen,Anne Uyttebroeck,A. Van de Voorde,Hugo Vanderstichele	2000	20
19	Aberrant splicing in the presenilin-1 intron 4 mutation causes presenile Alzheimers disease by increased a beta 42 secretion The American Journal of Human Genetics ·Marc Cruts,C. De Jonghe,Andi Shahaj,Carolyn Tysoe,Andrew Singleton,Hugo Vanderstichele,Wendy S. Meschino,Bart Dermaut,Athira Anilkumar S,H. Backhovens,Eugeen Vanmechelen,Christopher M. Morris,John Hardy,อารยา ดําเรือง,刘宝强,Christine Van Broeckhoven	1999	10
20	In vitro maturation of bovine oocytes in the presence of bovine activin A does not affect the number of embryos Animal Reproduction Science ·F. Izadyar,E. Zeinstra,B. Colenbrander,Hugo Vanderstichele,M.M. Bevers	1996	32

About Hugo Vanderstichele

Hugo Vanderstichele is a scholar working on Psychiatry and Mental health, Physiology and Neurology, having authored 156 papers that have together received 14.8k indexed citations. Recurring topics across this work include Alzheimer's disease research and treatments (106 papers), Dementia and Cognitive Impairment Research (72 papers), Parkinson's Disease Mechanisms and Treatments (17 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (14 papers), Computational Drug Discovery Methods (12 papers), Neurological Disease Mechanisms and Treatments (11 papers), S100 Proteins and Annexins (10 papers) and Statistical Methods in Clinical Trials (9 papers). The work is most often cited by research in Psychiatry and Mental health (6.6k citations), Physiology (10.8k citations) and Neurology (2.5k citations). Hugo Vanderstichele has collaborated with scholars based in Belgium, Sweden and United States. Frequent co-authors include Kaj Blennow, Eugeen Vanmechelen, Pia Davidsson, Niels Andreasen, Lennart Minthon, Wim Annaert, Paul Säftig, Bart De Strooper, Katleen Craessaerts and Leslie M. Shaw. Their work appears in journals such as Alzheimer s & Dementia, Journal of Alzheimer s Disease, Alzheimer s Research & Therapy, Neurobiology of Aging and Clinical Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact